TP53 and cancer: In the future, the development of innovative variant specific inhibitors targeting frequent TP53 and KRAS variants [58], or novel modalities such as cell-based, antisense nucleotide or gene replacement/editing therapies [42], being piloted in specific cancer entities or rare genetic diseases [24], might also prove valuable for patients genetic tumor syndromes.